Arpida files iclaprim in EU for infections
This article was originally published in Scrip
Executive Summary
Arpida has filed its lead product, intravenous antibiotic iclaprim, with the EMEAfor the treatment of complicated skin and soft tissue infections (cSSTI). The company filed it with the US FDA in March (Scrip Online, March 20th, 2008) and the agency has set a PDUFA user fee goal date of January 16th, 2009 for the application.